2023
DOI: 10.1007/978-3-031-28536-3_13
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 Vaccination in Persons with Diabetes: How they Work

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…A number of COVID‐19 vaccine preparations are now available, with administration currently recommended for all persons with diabetes. 12 Although some evidence suggests greater likelihood of thrombotic and coronary events among persons having COVID with the Janssen and Oxford‐AstraZeneca vaccines, the mRNA vaccines were associated with reduction in such events, 13 and a study from Hong Kong comparing 3218 unvaccinated persons with 5248 who had been vaccinated showed reduction in post‐COVID MI or stroke among persons with underlying CVD, with what appeared to be progressively greater reduction in such events with increasing number of doses either of an mRNA vaccine or a whole inactivated virus vaccine. 14 There are population studies suggesting potential adverse events.…”
mentioning
confidence: 99%
“…A number of COVID‐19 vaccine preparations are now available, with administration currently recommended for all persons with diabetes. 12 Although some evidence suggests greater likelihood of thrombotic and coronary events among persons having COVID with the Janssen and Oxford‐AstraZeneca vaccines, the mRNA vaccines were associated with reduction in such events, 13 and a study from Hong Kong comparing 3218 unvaccinated persons with 5248 who had been vaccinated showed reduction in post‐COVID MI or stroke among persons with underlying CVD, with what appeared to be progressively greater reduction in such events with increasing number of doses either of an mRNA vaccine or a whole inactivated virus vaccine. 14 There are population studies suggesting potential adverse events.…”
mentioning
confidence: 99%